EMPIRI receives $500K
Excited and grateful that we received $500K from an angel investor, enabling us to move forward with our CLIA LDT certification and prototype testing for CAL, a first-in-class precision cancer diagnostic instrument.
top of page
EMPIRI INC.
Search
Recent Posts
See AllSan Francisco, CA, Jan 8, 2023– EMPIRI today announced that it is presenting at Biotech Showcase™ 2023. This year, registered attendees can view EMPIRI’s presentation live, and also access a recorded
At the 11th annual Texas Life Science Forum, held on November 8, 2022, EMPIRI Inc. was once again recognized as one of the Rice Alliance Most Promising Life Science Companies for our E-Slice technolog
EMPIRI scientist Thomas Gallup presents his poster "Single Cell RNA-sequencing Analysis from Clinical Trials Needle Biopsy Cores" at the GCC Single Cell Omics on October 26, 2022. GCC, an inter-insti
bottom of page